Insurance Barriers and Costs Limit Access to Blood Cancer Oral Medications

A new nationwide study led by the Perelman School of Medicine at the University of Pennsylvania highlights that patients with blood cancers face significant insurance hurdles and high out-of-pocket costs when accessing specialty oral anticancer drugs. This research underscores the financial and systemic challenges impacting treatment accessibility for these patients.

Originally published by gnews